Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$8.58
+0.17 (+2.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $191.1M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.5B
P/E
20.9x
↑EV/EBITDA
9.9x
↓ROE
7.5%
↑Gross Margin
61.2%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.0%
FCF CAGR
-51.0%
FCF margin
1.0%
FCF / Net income
0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.76B · net income $449.6M · FCF $38.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.76B | $3.76B | $4.00B | $4.12B | $4.38B |
| Net Income | $449.6M | $449.6M | $397.2M | $563.1M | $749.4M |
| EBITDA | $763.0M | $763.0M | $728.2M | $864.0M | $1.07B |
| EPS | 0.45 | 0.45 | 0.40 | 0.57 | 0.76 |
| Gross Margin | 61.2% | 61.2% | 57.5% | 52.9% | 58.2% |
| Operating Margin | 13.0% | 13.0% | 17.7% | 16.0% | 17.2% |
| Net Margin | 12.0% | 12.0% | 9.9% | 13.7% | 17.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.01 | 0.04 | 0.06 |
| Current Ratio | 3.32 | 3.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $38.4M | $38.4M | $191.1M | $360.9M | $326.7M |
| Returns | |||||
| ROE | 7.5% | 7.5% | 6.8% | 9.7% | 13.7% |
| Valuation | |||||
| P/E | 20.93 | 20.93 | 24.53 | 21.40 | 14.78 |
| EV/EBITDA | 9.93 | 9.93 | 11.56 | 12.28 | 9.06 |
| P/B | 1.42 | 1.42 | 1.67 | 2.08 | 2.03 |
| Growth & Yield | |||||
| Revenue Growth | -6.0% | -6.0% | -3.0% | -5.9% | — |
| EPS Growth | 12.5% | 12.5% | -29.8% | -24.8% | — |
| Dividend Yield | 3.5% | 3.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
19.2%
EPS terminal req.
$0.76
Spread vs growth
-6.7%
5Y implied EPS CAGR
15.4%
EPS terminal req.
$0.92
Spread vs growth
-2.9%
10Y implied EPS CAGR
12.7%
EPS terminal req.
$1.48
Spread vs growth
-0.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.9%
Start / end P/E
23.2x → 19.1x
EPS bridge
0.40 → 0.45
Residual
-2.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.